Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
August 2025—EntroGen announced that its CRCdx RAS mutation detection kit has received national coverage from the Centers for Medicare and Medicaid Services. CRCdx is an FDA-approved, real-time PCR-based companion diagnostic for use in identifying patients eligible for treatment with Vectibix (panitumumab), based on the absence of KRAS and NRAS mutations.
August 2025—Revvity announced the launch of its IDS i20 analytical random access platform from Euroimmun, enabling full automation of chemiluminescence immunoassays. The CE-marked and FDA-listed IDS i20 allows users to simultaneously run 20 analytes from six diagnostic specialties on a single device. The specialties include endocrinology, allergy, autoimmune and infectious disease testing, testing for Alzheimer’s disease, and therapeutic drug monitoring. The instrument can process up to 140 tests per hour and features continuous loading of samples and reagents as well as integrated cooling of ready-to-use reagent cartridges. It is for in vitro diagnostic use.
July 2025—StaffReady has released a mobile app for its StaffReady Scheduling. The app is available on Apple and Android devices and offers StaffReady’s Calendar feature for users to easily view a schedule, request PTO, or make detailed shift requests, such as giveaways, trades, or bids. In addition, the company offers a weekly educational newsletter on its new website. It provides content specific to ancillary markets such as laboratories, pharmacies, and physical therapy/rehab departments and focuses on trends that affect workforce management in health care.
July 2025—The Food and Drug Administration has approved the de novo application for Randox Laboratories’ first companion diagnostic, the Randox ConcizuTrace ELISA. The test, developed in collaboration with Novo Nordisk, is intended for the quantitative measurement of concizumab-mtci concentration in human 3.2 percent citrated plasma samples from patients with hemophilia A and B four weeks after the initiation of treatment. The measurement of the concentration is used for dose adjustment decision in accordance with the drug label.
July 2025—Bio-Rad Laboratories will present an array of clinical diagnostic-related offerings at this year’s Association for Diagnostics and Laboratory Medicine Clinical Lab Expo in Chicago, July 27–31. An industry workshop titled “From Waste to Wow: Optimizing Your Quality Control Workflow” is designed to provide attendees with strategies to streamline QC management across multihospital systems for systemwide efficiency, reduce waste streams in clinical chemistry, and recognize patient-based real-time QC to improve lab QC processes.
July 2025—ARUP Laboratories now provides a blood test for phosphorylated tau 217 to assist in identifying whether symptoms of cognitive decline in patients ages 60 years and older are related to Alzheimer’s disease pathology.
July 2025—BD announced FDA 510(k) clearance for the BD Phoenix M50 automated microbiology solution and BDXpert system on the BD Synapsys informatics solution, leveraging rapid identification and antimicrobial susceptibility testing algorithms to assist in interpreting complex diagnostic data to help ensure accurate and reliable diagnoses related to antimicrobial resistance. BDXpert is an automated, rule-based system that analyzes ID and AST results from the BD Phoenix M50 system.
July 2025—Techcyte announced the launch of its wet mount iodine solution for research use only in the United States. The AI-assisted screening tool is designed to help users locate, count, and preclassify parasites from iodine-stained fecal slides. The solution is part of Techcyte’s Fusion parasitology suite, which includes the company’s trichrome and modified acid fast solutions.
July 2025—BioMérieux has agreed to acquire Day Zero Diagnostics, an infectious disease diagnostics company, with the aim of enhancing BioMérieux’s capabilities in next-generation sequencing and rapid diagnostics. Day Zero Diagnostics, based in Watertown, Mass., has developed technologies that integrate direct from whole blood sample preparation, sequencing, and advanced infectious disease and antimicrobial susceptibility testing analytics. The sequencing-based rapid diagnostic in development can identify the species and antibiotic resistance profile of a bacterial pathogen within hours.
July 2025—Diasorin has received 510(k) clearance from the FDA for its Liaison Plex Gram-positive blood culture assay. The assay detects 17 targets (13 Gram-positive bacteria and four relevant resistance gene targets) in less than two hours and features Diasorin’s proprietary NanoGrid technology, which allows the detection of nucleic acids without the need for conventional amplification reactions.
